NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences’ Phase 3 valbenazine trial for dyskinetic cerebral palsy failed to meet its primary endpoint, revealing key lessons for rare‑disease drug development and investor strategy.

Neurocrine Biosciences will present at the Canaccord Genuity 45th Annual Growth Conference, where its recent stock performance and financial metrics will be discussed.

Neurocrine Biosciences is set to present at the Canaccord Genuity Conference, but its flagging stock price and valuation metrics raise concerns about the company’s financial performance.

Neurocrine Biosciences has reported significant Q2 growth, exceeding market expectations and sending its stock price soaring.

Neurocrine Biosciences Inc. has exceeded expectations with a 17% year-over-year growth in total net product sales, driven by strong performance of its key products INGREZZA and CRENESSITY.

Neurocrine Biosciences’ stock price surges as positive results from clinical studies demonstrate the effectiveness of its treatments for rare genetic conditions, including classic congenital adrenal hyperplasia.

Neurocrine Biosciences is set to release its Q2 2025 financial results, which will be closely watched to determine if the company’s stock price is justified.

Neurocrine Biosciences has scheduled a conference call to discuss its Q2 2025 financial results, with details to be announced separately.

Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-01435, a high-risk, high-reward move that could be a game-changer for the company, but also poses significant consequences if it fails.

Neurocrine Biosciences has initiated a Phase 1 clinical study for its new treatment, NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist.